{"transactions":[{"id":704825,"issuer":{"id":4644,"kind":"organization","name":"Freenome, Inc.","symbol":"FRNM"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Dir, Ofc, 10% Ownr"}}],"security":"Class B Ordinary Shares","published_at":"2026-07-22T23:18:22.000Z","date":"2026-07-20","kind":"exercise","planned":false,"acquired":false,"shares":2066250,"ownership":{"direct":false,"nature":"By Perceptive Capital Solutions Holdings"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. (\"Old Freenome\"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the \"BCA\"), on July 20, 2026 (the \"Closing Date\"), the Issuer consummated its business combination with Old Freenome (the \"Business Combination\"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. (\"Old Freenome\"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the \"BCA\"), on July 20, 2026 (the \"Closing Date\"), the Issuer consummated its business combination with Old Freenome (the \"Business Combination\"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. (\"Old Freenome\"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the \"BCA\"), on July 20, 2026 (the \"Closing Date\"), the Issuer consummated its business combination with Old Freenome (the \"Business Combination\"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. (\"Old Freenome\"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the \"BCA\"), on July 20, 2026 (the \"Closing Date\"), the Issuer consummated its business combination with Old Freenome (the \"Business Combination\"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by Perceptive Capital Solutions Holdings (the \"Sponsor\"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2066250},"source":{"system":"sec-edgar","filing":"0001746738-26-000003","document":"form4-07222026_110718.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2017526/000174673826000003/form4-07222026_110718.xml","form_type":"4"}},{"id":704824,"issuer":{"id":4644,"kind":"organization","name":"Freenome, Inc.","symbol":"FRNM"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Dir, Ofc, 10% Ownr"}}],"security":"Common Stock","published_at":"2026-07-22T23:18:22.000Z","date":"2026-07-20","kind":"exercise","planned":false,"acquired":true,"shares":2066250,"ownership":{"direct":false,"nature":"By Perceptive Capital Solutions Holdings"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Business Combination Agreement, dated December 5, 2025 and amended on July 20, 2026 by and among the Issuer, Freenome Holdings, Inc. (\"Old Freenome\"), StarNet Merger Sub I, Corp., a wholly-owned subsidiary of the Issuer and StarNet Merger Sub II, LLC, a wholly owned subsidiary of the Issuer (the \"BCA\"), on July 20, 2026 (the \"Closing Date\"), the Issuer consummated its business combination with Old Freenome (the \"Business Combination\"). In connection with the closing of Business Combination, the Issuer's Class B Ordinary Shares converted into Class A Ordinary Shares on a one-to-one basis and subsequently converted into shares of Common Stock on a one-to-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by Perceptive Capital Solutions Holdings (the \"Sponsor\"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor."}],"balance_after":2352500,"source":{"system":"sec-edgar","filing":"0001746738-26-000003","document":"form4-07222026_110718.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017526/000174673826000003/form4-07222026_110718.xml","form_type":"4"}},{"id":1396938,"issuer":{"id":7926,"kind":"organization","name":"Adagio Medical Holdings, Inc.","symbol":"ADGM"},"owners":[{"id":87180,"kind":"organization","name":"ARYA Sciences Holdings IV","position":1,"cik":"0001838903","reported_name":"ARYA Sciences Holdings IV","relationship":{"ten_percent_owner":true}},{"id":29191,"kind":"person","name":"Stone Adam Leo","position":2,"cik":"0001727440","reported_name":"Stone Adam Leo","relationship":{"ten_percent_owner":true}},{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":3,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-10-01T20:35:55.000Z","date":"2024-09-27","kind":"other","planned":false,"acquired":false,"shares":3501600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 27, 2024, ARYA Sciences Holdings IV (the \"Sponsor\") effectuated a pro rata distribution for no consideration to its shareholders of its shares of common stock, par value $0.0001 per share (the \"Common Stock\"), of Adagio Medical Holdings, Inc. (f/k/a/ Aja HoldCo, Inc.) (the \"Issuer\"), including 1,147,500 shares of Common Stock that are subject to share price trigger vesting (the \"Earn-Out Shares\"). Such Earn-Out Shares (i) will vest if, prior to the tenth anniversary (the \"Earn-Out Period\") of the closing (the \"Closing\") of the business combination by and among ARYA Sciences Acquisition Corp IV, the Sponsor and the Issuer, the post-Closing share price of Common Stock equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period, or (ii) will automatically be forfeited and cancelled if the foregoing vesting condition is not fulfilled within the Earn-Out Period."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 27, 2024, ARYA Sciences Holdings IV (the \"Sponsor\") effectuated a pro rata distribution for no consideration to its shareholders of its shares of common stock, par value $0.0001 per share (the \"Common Stock\"), of Adagio Medical Holdings, Inc. (f/k/a/ Aja HoldCo, Inc.) (the \"Issuer\"), including 1,147,500 shares of Common Stock that are subject to share price trigger vesting (the \"Earn-Out Shares\"). Such Earn-Out Shares (i) will vest if, prior to the tenth anniversary (the \"Earn-Out Period\") of the closing (the \"Closing\") of the business combination by and among ARYA Sciences Acquisition Corp IV, the Sponsor and the Issuer, the post-Closing share price of Common Stock equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period, or (ii) will automatically be forfeited and cancelled if the foregoing vesting condition is not fulfilled within the Earn-Out Period."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman had voting and investment discretion with respect to any shares of Common Stock that were held of record by the Sponsor and may be deemed to have shared beneficial ownership of any shares of Common Stock that were held directly by the Sponsor."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-042486","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2006986/000114036124042486/form4.xml","form_type":"4"}},{"id":1445326,"issuer":{"id":88618,"kind":"organization","name":"ARYA Sciences Acquisition Corp IV","symbol":"ARYD"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Financial Officer"}}],"security":"Class B ordinary shares","published_at":"2024-08-01T01:40:05.000Z","date":"2024-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2647500,"ownership":{"direct":false,"nature":"By ARYA Sciences Holdings IV"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by ARYA Sciences Holdings IV (the \"Sponsor\"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":2647500},"source":{"system":"sec-edgar","filing":"0001140361-24-035164","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1746738/000114036124035164/form4.xml","form_type":"4"}},{"id":1445325,"issuer":{"id":88618,"kind":"organization","name":"ARYA Sciences Acquisition Corp IV","symbol":"ARYD"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Financial Officer"}}],"security":"Class B ordinary shares","published_at":"2024-08-01T01:40:05.000Z","date":"2024-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000000,"ownership":{"direct":false,"nature":"By ARYA Sciences Holdings IV"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the \"Sponsor Letter Agreement\"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration."},{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the \"Sponsor Letter Agreement\"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the \"Sponsor Letter Agreement\"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the \"Sponsor Letter Agreement\"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"In connection with the execution of the Business Combination Agreement, the Reporting Person entered into that certain Sponsor Letter Agreement, dated as of February 13, 2024, by and among the Reporting Person, the Issuer, HoldCo, Adagio and certain other individuals (the \"Sponsor Letter Agreement\"). Pursuant to the Sponsor Letter Agreement, the Reporting Person agreed to forfeit 1,000,000 Class B ordinary shares at, and subject to, the closing of the Business Combination for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by ARYA Sciences Holdings IV (the \"Sponsor\"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor."}],"balance_after":2647500,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001140361-24-035164","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1746738/000114036124035164/form4.xml","form_type":"4"}},{"id":1445324,"issuer":{"id":88618,"kind":"organization","name":"ARYA Sciences Acquisition Corp IV","symbol":"ARYD"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Financial Officer"}}],"security":"Class A ordinary shares","published_at":"2024-08-01T01:40:05.000Z","date":"2024-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":499000,"ownership":{"direct":false,"nature":"By ARYA Sciences Holdings IV"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the Business Combination Agreement, dated February 13, 2024, by and among the Issuer, Adagio Medical Holdings, Inc. (f/k/a Aja HoldCo, Inc.) (\"HoldCo\"), Aja Merger Sub 1 (\"Merger Sub 1\"), Aja Merger Sub 2, Inc. (\"Merger Sub 2\") and Adagio Medical, Inc. (\"Adagio\") (the \"Business Combination Agreement\" and the transactions contemplated thereby, the \"Business Combination\"), Merger Sub merged with and into the Issuer and Merger Sub 2 merged with and into Adagio, with each of the Issuer and Adagio becoming a wholly owned subsidiary of HoldCo, and the Reporting Person's ordinary shares of the Issuer were automatically converted into shares of common stock of HoldCo, par value $0.0001 per share (the \"New Adagio Common Stock\"), on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Footnote 1 Continued) 1,147,500 of such shares of New Adagio Common Stock will be subject to share trigger price vesting and will vest if, prior to the tenth anniversary of the Business Combination closing, the post-closing share price of HoldCo equals or exceeds $24.00 per share for any 20 trading days within any 30 trading day period."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by ARYA Sciences Holdings IV (the \"Sponsor\"). The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-035164","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746738/000114036124035164/form4.xml","form_type":"4"}},{"id":1477412,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T22:03:29.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date."}],"balance_after":45000,"derivative":{"exercise_price":2.56,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001062993-24-012727","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000106299324012727/form4.xml","form_type":"4"}},{"id":1479080,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-06-14T20:10:10.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":0.31,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-073651","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746738/000095017024073651/ownership.xml","form_type":"4"}},{"id":1481007,"issuer":{"id":4644,"kind":"organization","name":"Freenome, Inc.","symbol":"FRNM"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Business Officer"}}],"security":"Class A ordinary shares","published_at":"2024-06-13T20:37:08.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":286250,"price":10,"value":2862500.0,"ownership":{"direct":false,"nature":"By Perceptive Capital Solutions Holdings"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported Class A ordinary shares were purchased in a private placement by Perceptive Capital Solutions Holdings (the \"Sponsor\") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-279598)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor."}],"balance_after":286250,"source":{"system":"sec-edgar","filing":"0001140361-24-030023","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017526/000114036124030023/form4.xml","form_type":"4"}},{"id":1836434,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-07-06T01:49:08.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on June 30, 2024, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":4.11,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-23-031867","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746738/000095017023031867/ownership.xml","form_type":"4"}},{"id":1849708,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-21T00:52:46.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date."}],"balance_after":45000,"derivative":{"exercise_price":3.97,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-23-016073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000089924323016073/doc4.xml","form_type":"4"}},{"id":2225506,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2022-06-21T20:06:24.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":7250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on the earlier of (i) June 16, 2023 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":7250,"derivative":{"exercise_price":5.09,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":7250},"source":{"system":"sec-edgar","filing":"0000899243-22-023342","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746738/000089924322023342/doc4.xml","form_type":"4"}},{"id":2228084,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T21:43:59.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":86467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuous status as a \"Service Provider\" (as defined in the Issuer's 2021 Equity Incentive Plan) through each vesting date, the shares subject to the Option shall vest on a monthly basis for twelve consecutive months, on the same day of the month as the Grant Date.  The Grant Date was June 15, 2022."}],"balance_after":86467,"derivative":{"exercise_price":2.7,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":86467},"source":{"system":"sec-edgar","filing":"0001062993-22-015188","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000106299322015188/form4.xml","form_type":"4"}},{"id":2633286,"issuer":{"id":137308,"kind":"organization","name":"ARYA Sciences Acquisition Corp V","symbol":"ARYE"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Financial Officer"}}],"security":"Class A ordinary shares","published_at":"2021-07-15T17:53:36.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":499000,"price":10,"value":4990000.0,"ownership":{"direct":false,"nature":"By ARYA Sciences Holdings V"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported Class A ordinary shares were purchased in a private placement by ARYA Sciences Holdings V (the \"Sponsor\") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-257335)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor."}],"balance_after":499000,"source":{"system":"sec-edgar","filing":"0001140361-21-024476","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1852432/000114036121024476/form4.xml","form_type":"4"}},{"id":2672244,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2021-06-11T21:32:39.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":44435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"In connection with the appointment of the Reporting Person to the board of directors of Nautilus (the \"Board\"), the Board granted on June 9, 2021 the Reporting Person an Initial Award (as defined in the Company's Outside Director Compensation Policy and in accordance with Nautilus' 2021 Equity Incentive Plan (the \"Plan\"). Subject to the Reporting Person's continuous status as a \"Service Provider\" (as defined in the the Plan), the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the Initial Award's grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). The grant date is June 9, 2021."},{"field":"kind","element":"transactionCoding","label":"F4","text":"In connection with the appointment of the Reporting Person to the board of directors of Nautilus (the \"Board\"), the Board granted on June 9, 2021 the Reporting Person an Initial Award (as defined in the Company's Outside Director Compensation Policy and in accordance with Nautilus' 2021 Equity Incentive Plan (the \"Plan\"). Subject to the Reporting Person's continuous status as a \"Service Provider\" (as defined in the the Plan), the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the Initial Award's grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). The grant date is June 9, 2021."}],"balance_after":44435,"derivative":{"exercise_price":11.16,"exercise_date":"2021-06-09","expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":44435},"source":{"system":"sec-edgar","filing":"0001140361-21-020674","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000114036121020674/form4.xml","form_type":"4"}},{"id":2672243,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true}}],"security":"Class B ordinary shares","published_at":"2021-06-11T21:32:39.000Z","date":"2021-06-09","kind":"exercise","acquired":false,"shares":3647500,"ownership":{"direct":false,"nature":"ARYA Sciences Holdings III"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III (\"ARYA\"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the \"Business Combination\"), ARYA domesticated as a Delaware corporation (the \"Domestication\") and changed its name to \"Nautilus Biotechnology, Inc.\" (\"Nautilus\"). In connection with the Domestication, ARYA Sciences Holdings III's (the \"Sponsor\") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading \"Description of Securities--Founder Shares\"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III (\"ARYA\"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the \"Business Combination\"), ARYA domesticated as a Delaware corporation (the \"Domestication\") and changed its name to \"Nautilus Biotechnology, Inc.\" (\"Nautilus\"). In connection with the Domestication, ARYA Sciences Holdings III's (the \"Sponsor\") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading \"Description of Securities--Founder Shares\"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III (\"ARYA\"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the \"Business Combination\"), ARYA domesticated as a Delaware corporation (the \"Domestication\") and changed its name to \"Nautilus Biotechnology, Inc.\" (\"Nautilus\"). In connection with the Domestication, ARYA Sciences Holdings III's (the \"Sponsor\") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading \"Description of Securities--Founder Shares\"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III (\"ARYA\"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the \"Business Combination\"), ARYA domesticated as a Delaware corporation (the \"Domestication\") and changed its name to \"Nautilus Biotechnology, Inc.\" (\"Nautilus\"). In connection with the Domestication, ARYA Sciences Holdings III's (the \"Sponsor\") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading \"Description of Securities--Founder Shares\"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III (\"ARYA\"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the \"Business Combination\"), ARYA domesticated as a Delaware corporation (the \"Domestication\") and changed its name to \"Nautilus Biotechnology, Inc.\" (\"Nautilus\"). In connection with the Domestication, ARYA Sciences Holdings III's (the \"Sponsor\") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading \"Description of Securities--Founder Shares\"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman (the \"Reporting Person\"). As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":3647500},"source":{"system":"sec-edgar","filing":"0001140361-21-020674","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000114036121020674/form4.xml","form_type":"4"}},{"id":2672242,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-06-11T21:32:39.000Z","date":"2021-06-09","kind":"exercise","acquired":true,"shares":499000,"ownership":{"direct":false,"nature":"ARYA Sciences Holdings III"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with the Business Combination, the Sponsor's private placement shares, par value $0.0001 per share, of ARYA automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the Business Combination, the Sponsor's private placement shares, par value $0.0001 per share, of ARYA automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman (the \"Reporting Person\"). As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":499000,"source":{"system":"sec-edgar","filing":"0001140361-21-020674","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000114036121020674/form4.xml","form_type":"4"}},{"id":2672241,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true}}],"security":"Class A ordinary shares","published_at":"2021-06-11T21:32:39.000Z","date":"2021-06-09","kind":"exercise","acquired":false,"shares":499000,"ownership":{"direct":false,"nature":"ARYA Sciences Holdings III"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with the Business Combination, the Sponsor's private placement shares, par value $0.0001 per share, of ARYA automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the Business Combination, the Sponsor's private placement shares, par value $0.0001 per share, of ARYA automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman (the \"Reporting Person\"). As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-21-020674","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000114036121020674/form4.xml","form_type":"4"}},{"id":2672240,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-06-11T21:32:39.000Z","date":"2021-06-09","kind":"exercise","acquired":true,"shares":3647500,"ownership":{"direct":false,"nature":"ARYA Sciences Holdings III"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III (\"ARYA\"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the \"Business Combination\"), ARYA domesticated as a Delaware corporation (the \"Domestication\") and changed its name to \"Nautilus Biotechnology, Inc.\" (\"Nautilus\"). In connection with the Domestication, ARYA Sciences Holdings III's (the \"Sponsor\") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading \"Description of Securities--Founder Shares\"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the Business Combination Agreement, dated February 7, 2021, by and among ARYA Sciences Acquisition Corp III (\"ARYA\"), Mako Merger Sub, Inc. and Nautilus Biotechnology, Inc. (the transactions contemplated thereby, the \"Business Combination\"), ARYA domesticated as a Delaware corporation (the \"Domestication\") and changed its name to \"Nautilus Biotechnology, Inc.\" (\"Nautilus\"). In connection with the Domestication, ARYA Sciences Holdings III's (the \"Sponsor\") Class B ordinary shares, par value $0.0001 per share, of ARYA, which were previously convertible into Class A ordinary shares of ARYA (as described in ARYA's registration statement on Form S-1 (File No. 333-239986) under the heading \"Description of Securities--Founder Shares\"), were automatically converted into shares of common stock of Nautilus, par value $0.0001 per share, on a one-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman (the \"Reporting Person\"). As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":3647500,"source":{"system":"sec-edgar","filing":"0001140361-21-020674","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000114036121020674/form4.xml","form_type":"4"}},{"id":2691394,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2021-05-28T22:28:37.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":7250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable on the earlier of (i) May 26, 2022 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date."}],"balance_after":7250,"derivative":{"exercise_price":7.24,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":7250},"source":{"system":"sec-edgar","filing":"0000899243-21-021191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746738/000089924321021191/doc4.xml","form_type":"4"}},{"id":2820751,"issuer":{"id":88618,"kind":"organization","name":"ARYA Sciences Acquisition Corp IV","symbol":"ARYD"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Financial Officer"}}],"security":"Class A ordinary shares","published_at":"2021-03-02T21:30:26.000Z","date":"2021-03-02","kind":"grant","acquired":true,"shares":499000,"price":10,"value":4990000.0,"ownership":{"direct":false,"nature":"By ARYA Sciences Holdings IV"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported Class A ordinary shares were purchased in a private placement by ARYA Sciences Holdings IV (the \"Sponsor\") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333- 252960)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and Michael Altman. As such, Messrs. Stone and Altman have voting and investment discretion with respect to the securities held of record by the Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by the Sponsor."}],"balance_after":499000,"source":{"system":"sec-edgar","filing":"0001140361-21-006908","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746738/000114036121006908/form4.xml","form_type":"4"}},{"id":3062097,"issuer":{"id":6679,"kind":"organization","name":"Nautilus Biotechnology, Inc."},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"Chief Financial Officer"}}],"security":"Class A ordinary shares","published_at":"2020-08-12T00:38:00.000Z","date":"2020-08-11","kind":"other","acquired":true,"shares":499000,"price":10,"value":4990000.0,"ownership":{"direct":false,"nature":"By ARYA Sciences Holdings III"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported Class A ordinary shares were purchased as Private Placement Shares by ARYA Sciences Holdings III (the \"Sponsor\") for $10.00 per share, as described under the heading \"Description of Securities \" in the Issuer's registration statement on Form S-1 (File No. 333- 239986)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the Class A ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the Class A ordinary shares held directly by the Sponsor."}],"balance_after":499000,"source":{"system":"sec-edgar","filing":"0001140361-20-018160","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808805/000114036120018160/form4.xml","form_type":"4"}},{"id":3116828,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Class A ordinary shares","published_at":"2020-06-09T20:23:14.000Z","date":"2020-06-09","kind":"other","acquired":true,"shares":499000,"price":10,"value":4990000.0,"ownership":{"direct":false,"nature":"By ARYA Sciences Holdings II"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported Class A ordinary shares are within 499,000 of the Issuer's Private Placement Units, as described under the heading \"Description of Securities \" in the Issuer's registration statement on Form S-1 (File No. 333- 238488), purchased by the ARYA Sciences Holdings II (the \"Sponsor\") for $10.00 per Private Placement Unit."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held by the Sponsor. The Sponsor is governed by a board of directors consisting of two directors, Adam Stone and the Reporting Person. As such, Mr. Stone and the Reporting Person have voting and investment discretion with respect to the Class A ordinary shares held of record by the Sponsor and may be deemed to have shared beneficial ownership of the Class A ordinary shares held directly by the Sponsor."}],"balance_after":499000,"source":{"system":"sec-edgar","filing":"0001140361-20-013458","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000114036120013458/form4.xml","form_type":"4"}},{"id":3165528,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":29190,"kind":"person","name":"ALTMAN MICHAEL SETH","position":1,"cik":"0001746738","reported_name":"ALTMAN MICHAEL SETH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-05-01T22:44:38.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in 36 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following April 30, 2020."}],"balance_after":14500,"derivative":{"exercise_price":16,"expiration_date":"2030-04-29","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0000899243-20-011753","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1746738/000089924320011753/doc4.xml","form_type":"4"}}]}